




July 2026 • Corporate Deck

RESPILIQ


the difference in COPD treatment



Hypercapnia

Elevated levels of CO_2

- **COPD** is a progressive lung disease
- COPD leads to elevated levels of CO_2 , a condition called **hypercapnia**
- Hypercapnia **poisons** the patient
- 90% of chronic hypercapnic COPD patients **die within 3-5 years**



Current patient journey

No drugs available to treat hypercapnia

Exhaust all pharmaceutical treatments

LAMA, LABA, ICS, PDE3/4, biologics, macrolides



Chronic Hypercapnia



Resort to **NIV**

6h/day mechanic
high pressure ventilation



Future patient journey

First in Class drug to treat hypercapnia

Exhaust all pharmaceutical treatments

LAMA, LABA, ICS, PDE3/4, biologics, macrolides




Chronic Hypercapnia



RESPLIQ

first in class therapeutic treatment
targeting hypercapnia



Disruptive Mode of Action

Breathing via the gut




RESPILIQ uses the human gut for CO₂ removal.

O₂ →



→ CO₂



Well-understood, local Mode of Action



Efficacy

Large animal model for hypercapnia established

- Established **novel large animal model** in cooperation with University Hospital Aachen
- Selected porcine (60kg) as **best surrogate to human** gastrointestinal tract
- Simulates **chronic hypercapnic respiratory failure** by means of a 24-hour initiation phase to saturate tissue with CO₂
- Primary readout: ΔPaCO_2
Arterial partial CO₂ is the well-established efficacy **surrogate to hypercapnia** endpoints:
 - mortality¹
 - quality of life¹
 - exacerbations²
 - hospitalizations²





¹ Köhnlein et al. Lancet Respir. Med. 2014.

² Murphy et al. JAMA 2017.

Preclinical Evaluation


Superior efficacy in hypercapnia treatment



RESPILIQ

Market opportunity

Country / region	Prevalence chronic hypercapnia in COPD [Million patients]
EU27+	3.0
USA	1.9
Japan	0.7
India	7.9
China	8.0
Worldwide	43



COGS expected at 1€ per daily treatment

KOL

Endorsements



Prof. Dr. med. Frits Franssen

Personalized treatment of COPD, pulmonary rehabilitation, individualized diagnostics and interventions.

Confirmed partner observational study in NIV patients.



Prof. Dr. med. Michael Dreher

Pulmonology and respiratory critical care medicine.

Confirmed Principal Investigator FiP trial RESPILIQ.



Prof. Dr. med. Gernot Marx

Operative intensive care medicine and intermediate care.


Foresees additional applications on ICU and in weaning.



Compelling competitive advantage for RESPILIQ



Non-Invasive Ventilation



Nasal High-Flow Therapy

RESPILIQ



Enteral CO₂ elimination

We aim to

- Replace current treatment
- Offer treatment to large underserved patient groups
- Avoid hospitalizations
- Reduce healthcare costs

Production & IP

Inhouse

- **In-depth** medical, technological and analytical **knowledge**
- QM / QC in place
 - **GMP** Pilot Plant in Aachen

Patents filed (5) – granted (3)

1. Prophylaxis and treatment of respiratory diseases
2. Formulation / Composition
3. Intensive Care Unit Application Method
4. Sport/Consumer Application
5. Production technologies



GMP pilot plant O11 in Aachen


Intellectual Property



Family	Patent	Filing date	Region	Ownership	Status
1	Composition of Carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose	15.08.2018	EP 3 610 860 A1 US 2021/0299 164	Full ownership O11	Granted in EU. Protects several applications as well as prophylaxis and treatment of respiratory disease. Patent claims revised for US, pending.
2	Coated active ingredient formulation for controlled in vivo uptake of CO2	27.10.2021	DE 10 2021 127 957 A1 DE 10 2022 124 227.7 WO 2023/072929 A1	Full ownership O11	Granted in AUS. Broad patent with wide range of claims allows ample possibilities to mitigate possible objections. Pending in EU / US.
3	Device for enteral absorption of CO2 and corresponding set	03.11.2023	DE 10 2023 130 381.3	Full ownership O11	Granting (AUS) in progress, for ICU application
4	Use of a CO2-absorbing formulation and ergogenic food supplement, in particular energy drink or sports drink	24.11.2023	DE 10 2023 130 381.3	Full ownership O11	Pending, extended to practically all relevant countries for this application
5	Process for the preparation of a particulate CO2-absorbing composite polymer material	17.06.2025	DE 10 2025 123 517.1	Full ownership O11	Pending
	Trademark "RESPILIQ"	23.11.2023	EUIPO #018800926	Full ownership O11	Granted
	FTO analysis (N10806.FTO) by FARAGO Patentanwälte	26.05.2023	Worldwide	-	no critical patents could be identified

Roadmap

Milestones & Financing



Founder led expert team



Founders



Dr. Richard Ramakers
CEO
[LinkedIn](#)



PD Dr. med. Ch Cornelissen
CMO
[LinkedIn](#)



Prof. Dr. med. St Jockenhövel
CSO
[LinkedIn](#)



Stefan Siebert M.Sc.
CMC
[LinkedIn](#)



Martin Blüggel
Board Chair
[LinkedIn](#)

Complementing Expert



Dr. Susanne Awe
Quality Management
[LinkedIn](#)



Cilia Sandhoff M.Sc.
Quality Control
[LinkedIn](#)



Dr. Tatjana Reinholz
Regulatory Affairs



Daniel Moritz M.Sc.
Finance
[LinkedIn](#)



Join our journey!

Mail ramakers@o11-biomedical.com

Address [Vaalser Straße 460](#)
[52074 Aachen](#)
[Germany](#)

Website www.o11-biomedical.com

